Identification of oncogenic mutations of BRAF (with the most common mutation being a glutamic acid for valine substitution at position 600 (BRAFV600E)) as the primary driver of aberrant activation of the pathway in melanoma has led to development of mutant BRAF inhibitors in the treatment of the disease [1, 3-5]. The gene discussed is BRAF; the disease is melanoma.